Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik Johnsen

Showing results (1-10 of 191) with videos related to

Pageof 20
Sort By:
Evidence-Based Mental Health|April 20, 2011
Review: metabolic side effects of second-generation antipsychoticsErik Johnsen
Evidence-Based Mental Health|July 28, 2009
Review: second generation antipsychotics are a heterogeneous drug classErik Johnsen
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|May 5, 2017
Erik Johnsen
Current Psychiatry Reports|March 15, 2012
Is rational antipsychotic polytherapy feasible? A selective reviewRune Andreas Kroken, Erik Johnsen
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|January 18, 2006
[Hyperprolactinemia induced by antipsychotic agents]Erik Johnsen, Hugo A Jørgensen
BMC Psychiatry|April 29, 2008
Effectiveness of second generation antipsychotics: a systematic review of randomized trialsErik Johnsen, Hugo A Jørgensen
Therapeutic Advances in Chronic Disease|January 24, 2013
Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulnessErik Johnsen, Rune A Kroken
Leukemia & Lymphoma|August 1, 2002
The CD19 compartment in myeloma includes a population of clonal cells persistent after high-dose treatmentThomas Rasmussen, Linda Jensen, Hans Erik Johnsen
Case Reports in Psychiatry|August 31, 2012
Priapism in antipsychotic drug use: a rare but important side effectIgne Sinkeviciute, Rune A Kroken, Erik Johnsen
Schizophrenia Research|July 13, 2024
NMDAR dysfunction and the regulation of dopaminergic transmission in schizophreniaGerard Eric Dwyer, Erik Johnsen, Kenneth Hugdahl
Pageof 20

Showing results (1-10 of 191) with videos related to

Sort By:
Pageof 20
Evidence-Based Mental Health|April 20, 2011
Review: metabolic side effects of second-generation antipsychoticsErik Johnsen
Evidence-Based Mental Health|July 28, 2009
Review: second generation antipsychotics are a heterogeneous drug classErik Johnsen
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|May 5, 2017
Erik Johnsen
Current Psychiatry Reports|March 15, 2012
Is rational antipsychotic polytherapy feasible? A selective reviewRune Andreas Kroken, Erik Johnsen
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|January 18, 2006
[Hyperprolactinemia induced by antipsychotic agents]Erik Johnsen, Hugo A Jørgensen
BMC Psychiatry|April 29, 2008
Effectiveness of second generation antipsychotics: a systematic review of randomized trialsErik Johnsen, Hugo A Jørgensen
Therapeutic Advances in Chronic Disease|January 24, 2013
Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulnessErik Johnsen, Rune A Kroken
Leukemia & Lymphoma|August 1, 2002
The CD19 compartment in myeloma includes a population of clonal cells persistent after high-dose treatmentThomas Rasmussen, Linda Jensen, Hans Erik Johnsen
Case Reports in Psychiatry|August 31, 2012
Priapism in antipsychotic drug use: a rare but important side effectIgne Sinkeviciute, Rune A Kroken, Erik Johnsen
Schizophrenia Research|July 13, 2024
NMDAR dysfunction and the regulation of dopaminergic transmission in schizophreniaGerard Eric Dwyer, Erik Johnsen, Kenneth Hugdahl
Pageof 20